Levitas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.98 M
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 2.50 M
- Revenue Growth 13.95%
- Profit Growth 249.68%
- Ebitda 67.64%
- Net Worth 122.62%
- Total Assets 14.85%
About Levitas Pharmaceuticals
Levitas Pharmaceuticals Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 April 2013 and has a history of 11 years and ten months. Its registered office is in Ernakulam, Kerala, India.
The Corporate was formerly known as Zeus Fashions Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.98 M.
The company currently has active open charges totaling ₹2.50 M.
Kalayil Siji, Jino Paul, and Shinu serve as directors at the Company.
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230KL2013PTC033766
- Company No.
033766
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2013
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Levitas Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalayil Siji  | Managing Director | 29-Oct-2015 | Current |
Financial Performance of Levitas Pharmaceuticals.
Levitas Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 13.95% increase. The company also saw a substantial improvement in profitability, with a 249.68% increase in profit. The company's net worth Soared by an impressive increase of 122.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Levitas Pharmaceuticals?
In 2018, Levitas Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Nov 2018 | Others | ₹2.50 M | Open |
How Many Employees Work at Levitas Pharmaceuticals?
Levitas Pharmaceuticals has a workforce of 2 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Levitas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Levitas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
